You are viewing: Switzerland Apheresis Market analysis
Part of: Apheresis Market (Global)

The Switzerland Apheresis Market was valued at $0.27 Million in 2026 and projected to reach to $0.32 Million by 2031, representing a compound annual growth rate of 3.0%. Switzerland's apheresis market demonstrates steady growth potential, supported by the country's advanced healthcare infrastructure and increasing clinical adoption of therapeutic apheresis procedures.

Switzerland Apheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Switzerland Apheresis Market Trends and Insights

  • This modest but steady expansion reflects Switzerland's advanced healthcare infrastructure and increasing adoption of therapeutic apheresis procedures in specialized medical centers.
  • Switzerland's mature healthcare system and high per-capita spending support the deployment of apheresis technologies across blood banks, hospitals, and specialized treatment facilities. The Swiss apheresis market benefits from strong regulatory frameworks, high treatment standards, and a well-established patient base requiring plasma exchange, cytapheresis, and other blood component separation therapies.
  • Switzerland's aging population and prevalence of autoimmune and hematologic disorders drive demand for apheresis procedures.
  • Between 2026 and 2031, Switzerland is expected to maintain steady market growth, supported by continued investment in healthcare infrastructure and clinical adoption of advanced apheresis systems..

Key Market Statistics

  • CAGR (2026-2031) 3.0% CAGR
  • Market Size, 2026 ~USD 0.27 Million
  • Forecast, 2031 ~USD 0.32 Million
  • Country Switzerland

Switzerland Apheresis Market Overview

Market Size & Growth :

Switzerland's apheresis market is valued at $0.27 million in 2026, with projected growth to $0.32 million by 2031, reflecting a steady 3.0% CAGR despite being significantly smaller than the global market expanding at 7.9%.

Advanced Healthcare Infrastructure :

Switzerland's mature and well-developed healthcare system supports specialized apheresis procedures across leading medical centers, with high adoption rates among hospitals and treatment facilities in major cities like Zurich, Basel, and Bern.

Therapeutic Applications :

Swiss medical centers increasingly utilize therapeutic apheresis for autoimmune disorders, hematologic conditions, and plasma exchange procedures, driven by clinical expertise and patient demand for advanced treatment modalities.

Regulatory Environment :

Switzerland's stringent regulatory framework and alignment with European medical device standards ensure high-quality apheresis equipment and procedures, supporting market credibility and healthcare provider confidence.

Switzerland Apheresis Market Dynamics

  • The 3.0% CAGR reflects a mature market with established medical practices and high treatment standards across specialized centers.
  • Growing awareness of apheresis benefits for autoimmune and hematologic conditions is expected to drive modest expansion through 2031. The Swiss market will likely benefit from continued investment in healthcare technology and rising patient demand for specialized treatments.
  • However, market growth remains constrained by the country's small population and already-high penetration of advanced therapies.
  • Strategic partnerships with European markets and integration of newer apheresis technologies may unlock additional opportunities for market participants..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • JOHNSON & JOHNSON

    Key Takeaways

    • Switzerland's apheresis market is valued at $0.27 million in 2026 and is forecast to reach $0.32 million by 2031 at a 3.0% CAGR.
    • Switzerland's advanced healthcare system and high treatment standards support consistent demand for therapeutic apheresis across specialized medical centers.
    • An aging Swiss population and rising prevalence of autoimmune disorders are key drivers of apheresis procedure adoption in Switzerland.
    • Switzerland's strong regulatory environment and healthcare infrastructure position it as a stable, mature market for apheresis technologies through 2031.

    Apheresis Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment CHINA (Technology)
    Forecast Period 2026–2031
    Growth Rate CAGR of 7.9% from 2026 to 2031
    Largest Segment BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS (End User)
    Market Size Base Year (Billions) ~USD 3.02 (2026)
    Revenue Forecast (Billions) ~USD 4.41 (2031)
    Segments Covered Technology, End User, Type, Application, Product, Disease Type, Procedure, Product 2021–2029

    Switzerland Apheresis Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Technology

    • Centrifugal Apheresis Devices
    • Centrifugation
    • Membrane Separation
    • Membrane Separators

    By End User

    • Blood Collection Centers & Blood Component Providers
    • Blood Collection Centers And Blood Component Providers
    • Hospitals & Transfusion Centers
    • Hospitals And Transfusion Centers
    • Other End Users

    By Type

    • Centrifugal Devices
    • Continuous Flow
    • Donor Apheresis
    • Intermittent Flow
    • Membrane Separators
    • Therapeutic Apheresis

    By Application

    • Erythrocytapheresis
    • Leukapheresis
    • Photopheresis
    • Plasmapheresis
    • Plateletpheresis

    By Product

    • Apheresis Devices
    • Apheresis Disposables
    • Devices
    • Disposables

    By Disease Type

    • Autoimmune Disorders
    • Blood Disorders
    • Cardiovascular Disorders
    • Metabolic Disorders
    • Neurologic Disorders
    • Other Disorders
    • Renal Disorders

    By Procedure

    • Automated Blood Collection (Donor Apheresis)
    • Erythrocytapheresis
    • Leukapheresis
    • Photopheresis
    • Plasmapheresis
    • Plateletpheresis
    • Therapeutic Apheresis

    By Product 2021–2029

    • Devices
    • Disposables

    SWITZERLAND: APHERESIS MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS18.419.119.920.721.622.623.624.74.4
    HOSPITALS AND TRANSFUSION CENTERS9.49.910.41111.512.212.913.65.5
    OTHER END USERS1.51.51.61.61.71.71.81.93.2
    TOTAL29.330.631.933.334.936.538.240.14.7

    Target Audience

    • Medical Device Manufacturers : Apheresis equipment and consumables manufacturers need Switzerland-specific market data to assess market viability, competitive positioning, and regulatory requirements for product commercialization in this advanced healthcare market.
    • Healthcare Facility Operators : Swiss hospitals and specialized treatment centers require market insights to justify apheresis program investments, benchmark utilization rates, and plan capital expenditures for equipment upgrades and facility expansion.
    • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in Switzerland need precise market sizing and growth forecasts to assess investment returns, identify acquisition targets, and evaluate market consolidation potential.
    • Pharmaceutical & Biotech Companies : Companies developing therapies requiring apheresis support need Switzerland market data to understand patient populations, treatment adoption rates, and commercial viability for therapeutic applications.
    • Healthcare Consultants & Advisors : Management consultants and healthcare advisors require Switzerland-specific apheresis market intelligence to support client strategy development, market entry planning, and competitive positioning recommendations.

    Key Companies in the Switzerland Apheresis Market

    CompanyHQOwnershipStrongest segments
    FRESENIUS MEDICAL CAREGermanyPublic CompanyOutpatient dialysis services (Care Delivery),Hemodialysis machines, consumables, and water systems,Peritoneal dialysis cyclers and solutions,
    INFOMED SAAustraliaPrivate CompanyMicrocat EPC and parts ordering (EPC, PartsBridge, Market, CRM),Superservice suite (Menus, Triage, Connect, Register),E-commerce platforms (SimplePart, INFODRIVE),
    HAIER BIOMEDICALChinaPublic CompanyLow temperature storage (ULT, pharmacy, blood bank, plasma, vaccine, cold/freezer rooms, transport),Laboratory equipment (incubators, biosafety cabinets, clean benches, sterilization, centrifuges, analytical instruments, consumables),Intelligent automation and RFID pharmacy solutions,
    JAFRON BIOMEDICAL CO., LTD.ChinaPublic CompanyHA series disposable hemoperfusion cartridges,BS series plasma bilirubin adsorption columns,Blood purification machines and related equipment,

    FRESENIUS MEDICAL CARE

    Fresenius Medical Care is a German public company founded in 1996 that operates as a global healthcare provider with over 108,000 employees. The company specializes in dialysis products and services for patients with chronic kidney failure.

    INFOMED SA

    Infomed SA is an Australian private company established in 1987 with 300 employees operating in the medical device and healthcare sector.

    HAIER BIOMEDICAL

    Haier Biomedical is a Chinese public company established in 2005 with 2,945 employees that manufactures biomedical equipment and laboratory instruments.

    JAFRON BIOMEDICAL CO., LTD.

    Jafron Biomedical Co., Ltd. is a Chinese public company founded in 1989 with 2,301 employees that develops and manufactures medical devices and biotechnology products.

    Reasons to Buy this Report

    • Precise Market Sizing : Obtain accurate market valuation data specific to Switzerland ($0.27M in 2026), enabling precise budget allocation and investment decisions for market entry or expansion strategies.
    • Growth Trajectory Insights : Understand Switzerland's 3.0% CAGR forecast through 2031, allowing stakeholders to benchmark performance against regional expectations and identify timing for product launches or facility investments.
    • Competitive Landscape Analysis : Gain detailed intelligence on Switzerland's specialized apheresis market dynamics, including key medical centers, treatment adoption rates, and competitive positioning within the mature Swiss healthcare ecosystem.
    • Regulatory & Compliance Framework : Access insights into Switzerland's stringent regulatory environment and European alignment, essential for medical device manufacturers and service providers planning market entry or compliance strategies.
    • Strategic Market Opportunities : Identify growth opportunities in therapeutic applications, emerging treatment modalities, and partnerships with Swiss healthcare institutions to capitalize on the country's advanced medical infrastructure.

    Frequently asked questions

    What is the current size of the apheresis market in Switzerland?

    The apheresis market in Switzerland is estimated at $0.27 million in 2026 and is projected to grow to $0.32 million by 2031.

    What is the CAGR for the apheresis market in Switzerland?

    Switzerland's apheresis market is expected to grow at a compound annual growth rate (CAGR) of 3.0% from 2026 to 2031.

    What factors drive apheresis demand in Switzerland?

    Key drivers include Switzerland's aging population, high prevalence of autoimmune and hematologic disorders, advanced healthcare infrastructure, and strong regulatory standards supporting therapeutic apheresis adoption.

    Which healthcare settings use apheresis technology in Switzerland?

    Apheresis technologies are deployed across Switzerland's blood banks, hospitals, and specialized treatment centers that provide plasma exchange, cytapheresis, and other blood component separation therapies.

    How does Switzerland's apheresis market compare to global trends?

    Switzerland's 3.0% CAGR reflects a mature, stable market with steady growth, compared to the global apheresis market CAGR of 7.9%, indicating Switzerland's market is growing more slowly due to its already-advanced healthcare penetration.

    RESEARCH METHODOLOGY

    This study involved the extensive use of both primary and secondary sources. The research process involved examining various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and key players' strategies.

    Secondary Research

    The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, Companies House documents, investor presentations, and SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the apheresis market. It was also used to obtain important information about key players, market classification & segmentation according to industry trends, down to the bottom level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply & demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the apheresis market. The primary sources from the demand side include medical OEMs, medical device ISOs, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights into key industry trends & key market dynamics.

    Apheresis Market 
 Size, and Share

    Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
    Note 2: Others include sales, marketing, and product managers.
    Note 3: Companies are classified into tiers based on their total revenue. As of 2025, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    In this report, the global apheresis market size was determined using revenue share analysis of leading players. For this purpose, key market players were identified, and their revenues from the apheresis business were determined using insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, including CEOs, directors, and marketing executives.

    To calculate the global market value, segmental revenues were derived from the revenue mapping of major solution/service providers. This process involves the following steps:

    • Generating a list of major global players operating in the apheresis market
    • Mapping annual revenues generated by major global players from the apheresis segment (or nearest reported business unit/service category)
    • Revenue mapping of key players to cover a major share of the global market as of 2025
    • Extrapolating the global value of the apheresis industry

    Apheresis Market Top Down and Bottom Up Approach

    Data Triangulation

    After arriving at the overall market size through the market size estimation process explained above, the global apheresis market was segmented and subsegmented. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the apheresis market was validated using both top-down and bottom-up approaches.

    Market Definition

    Apheresis is a medical technology and extracorporeal blood separation procedure in which whole blood is withdrawn from a donor or patient and processed through a device that separates specific blood components. The desired component is collected or treated, while the remaining blood components are returned to the individual. The process primarily uses centrifugation or membrane filtration to separate blood components.

    Apheresis encompasses both donor and therapeutic procedures and is widely used in transfusion medicine, hematology, oncology, nephrology, neurology, and immunology for blood component collection and the treatment of various disorders, including autoimmune diseases, hematologic conditions, and metabolic disorders.

    Key Stakeholders

    • Companies manufacturing apheresis devices & disposables
    • Original equipment manufacturing companies
    • Suppliers and distributors of apheresis devices & disposables
    • Healthcare service providers
    • Health insurance payers
    • Government bodies/municipal corporations
    • Regulatory bodies
    • Medical research institutes
    • Business research and consulting service providers
    • Venture capitalists
    • Market research and consulting firms

    Report Objectives

    • To define, describe, and forecast the global apheresis devices market based on product, type, procedure, technology, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth
      (such as drivers, restraints, opportunities, and challenges) along with the current trends
    • To strategically analyze micromarkets1 concerning individual growth trends, prospects, and contributions to the overall apheresis market
    • To analyze the opportunities in the global apheresis market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments concerning five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, expansions, strategic alliances, and acquisitions in the global apheresis market.
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global apheresis market report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of the top twelve companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to 10)

    Geographic Analysis

    • Further breakdown of the Rest of Europe's apheresis market into Russia, Finland, Switzerland, Turkey, the Czech Republic, the Netherlands, Norway, Poland, Portugal, Romania, Estonia, Austria, and Belgium
    • Further breakdown of the Rest of Asia Pacific’s apheresis market into Taiwan, New Zealand, and Sri Lanka
    • Further breakdown of the Rest of Latin America’s apheresis market into Uruguay, Costa Rica, Bolivia, Venezuela, and Paraguay

     

    Get the Full Apheresis Market Report

    Full forecast, segment splits, and company analysis for all Apheresis Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status